Recognize Disease Hallmarks Earlier for Improved Patient Outcomes
Gain Clarity Across Next Generation Non-Invasive Testing Technologies Revolutionizing Cancer Monitoring, MRD & Earlier Detection to Support Novel Pre-Metastatic Drug Development with Maximized Access
In the wake of new FDA guidance and exciting MRD partnership announcements between Grail & AstraZeneca, Amgen & Bristol Myers Squibb the liquid biopsy industry is experiencing a paradigm shift. Touted as having the potential to transform clinical practice as we know it, technical progress and mounting investment in premetastatic applications are creating huge industry-wide excitement for liquid biopsy-based screening & surveillance for novel precision drug development.
With technology maturity on the near horizon, the inaugural Liquid Biopsy Surveillance & Early Detection Summit is your only dedicated platform providing much-needed clarity on the industry’s emerging assays increasingly opening the doors to novel trial design and better patient outcomes.
As drug & diagnostic developers look to realize the commercial impact of early detection & MRD while shifting pipelines from the metastatic setting, here lies your best opportunity to harness game-changing technologies to define leading stratification, surrogate endpoint, and regulatory strategies – accelerating the delivery of breakthrough therapies into the clinic.
Providing a path forward for early detection & surveillance to become a widespread patient reality, unite with 80+ Translational, Biomarker, Clinical, Regulatory, Precision Medicine, Medical Affairs & Diagnostic experts at your only forum prioritizing liquid biopsy applications for earlier intervention.
Ensure you & your team stay ahead of the curve with unmissable intelligence this November!
2022 Speaker Faculty Included
Director, Oncology Translational Medicine Strategy & Portfolio
Executive Director, Translational Oncology Lead, Global Product Development, Oncology
Executive Director, Global Medical Affairs, Oncology, Precision Medicine
Why Are Experts Attending in 2022?
“To learn about the latest in early-stage cancer detection and treatment technologies and best practices; to understand how to facilitate their adoption and deployment; and to understand the regulatory and pubic policy environment affecting the industry”
Stephen Ezell, Vice President, Global Innovation Policy, and Director, Center for Life Sciences Innovation, Information Technology and Innovation Foundation
“Would be good to discuss with like-minded physicians and scientists who are working on MRD in cancers”
Arnab Basu, Medical Oncologist, O’Neal Comprehensive Cancer Center
“Looking forward to discussing the emerging clinical data and pathways towards clinical implantation for patient benefit”
Mohan Bolisetty, WW Medical Lead, Bristol Myers Squibb